Also known as: KLOW Blend · GHK-Cu/BPC-157/TB-500/KPV Stack · KLOW Peptide Blend
KLOW is a quadruple-peptide research blend combining GHK-Cu, BPC-157, TB-500, and KPV (Lys-Pro-Val). It builds on the GLOW formula by adding KPV — the C-terminal tripeptide of α-MSH with potent MC1R-mediated anti-inflammatory activity — making it particularly suited to research into inflammatory skin conditions, accelerated collagen remodelling, and tissue repair in inflamed environments.
KLOW extends the GLOW peptide blend by incorporating KPV (Lys-Pro-Val), a naturally occurring C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). KPV retains the full anti-inflammatory and immunomodulatory activity of α-MSH while being small enough for efficient tissue penetration — making it a potent addition to a regenerative peptide stack.
The four components address complementary aspects of tissue repair: GHK-Cu rebuilds extracellular matrix and resets aging gene expression; TB-500 restores vascularity through VEGF upregulation; BPC-157 modulates growth factor signalling and resolves nitric oxide dysregulation; and KPV directly suppresses NF-κB-mediated inflammatory cascades via melanocortin receptor 1 (MC1R) agonism.
KLOW is CAS-registered (67727-97-3), distinguishing it from GLOW as a defined blend with traceable identity. It is primarily researched for skin anti-aging, inflammatory skin repair, collagen synthesis, and as a multi-target wound healing protocol.
KPV (Lys-Pro-Val) binds melanocortin receptor 1 (MC1R) on keratinocytes, macrophages, and dendritic cells. MC1R activation inhibits NF-κB nuclear translocation, suppressing transcription of TNF-α, IL-1β, IL-6, and IL-8. This provides a receptor-mediated anti-inflammatory signal distinct from BPC-157's nitric oxide modulation — creating dual-pathway inflammatory control in KLOW.
GHK-Cu activates TGF-β and stimulates fibroblast production of collagen types I, III, and IV. It also modulates MMP activity — reducing collagen degradation while increasing synthesis. In an inflamed tissue environment, GHK-Cu's combined collagen-building and antioxidant copper chelation activity is particularly valuable.
TB-500 promotes angiogenesis and cell migration through actin dynamics and VEGF upregulation. BPC-157 amplifies growth hormone receptor expression and modulates VEGF, EGF, and FGF pathways. Together they ensure that remodelling tissue receives adequate blood supply and growth factor signalling to sustain the collagen synthesis driven by GHK-Cu.
KLOW adds KPV — a potent anti-inflammatory tripeptide (Lys-Pro-Val) derived from α-MSH — to the core GLOW stack. KPV's MC1R agonism gives KLOW a stronger anti-inflammatory and skin-calming profile, making it more suited to research into inflammatory skin conditions, rosacea, eczema, and accelerated tissue remodeling. Always verify component ratios with the supplier before dosing.
Cycling protocol mirrors the GLOW blend, governed primarily by TB-500 and BPC-157 research standards. The addition of KPV does not extend the recommended cycle length. In skin-focused research, longer topical cycles of the GHK-Cu component are standard — the injectable blend is cycled to assess response to the full four-component stack.
KPV's inclusion in KLOW is most relevant for skin conditions characterised by chronic inflammation (rosacea, eczema, psoriasis, post-procedure recovery), where standard collagen-building peptides are limited by the inflammatory microenvironment. KPV's MC1R agonism creates an anti-inflammatory platform that enables GHK-Cu to operate more effectively.
The CAS number 67727-97-3 corresponds to the registered blend composition. No randomised controlled trials have been published on the KLOW combination specifically — researchers should evaluate component-level literature independently.
Ask anything about KLOW — mechanisms, dosing protocols, interactions, or research comparisons.
GHK-Cu is a naturally occurring copper-binding tripeptide with the sequence Gly-His-Lys. It plays a critical role in wou…
Argireline (Acetyl Hexapeptide-3) is a synthetic hexapeptide acetylated at the N-terminus that mimics the N-terminal dom…
Matrixyl (Palmitoyl Pentapeptide-4) is a lipophilic pentapeptide consisting of a KTTKS collagen-derived sequence conjuga…
GLOW is a 70 mg multi-peptide research blend combining GHK-Cu (50 mg), TB-500 (10 mg), and BPC-157 (10 mg). The high GHK…